IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 202 filers reported holding IMPAX LABORATORIES INC in Q4 2017. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,938,000 | +18.5% | 151,134 | +1.5% | 0.00% | 0.0% |
| Q4 2017 | $2,480,000 | -17.9% | 148,859 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $3,019,000 | +31.7% | 148,419 | +4.2% | 0.00% | 0.0% |
| Q2 2017 | $2,292,000 | +37.4% | 142,452 | +8.1% | 0.00% | +100.0% |
| Q1 2017 | $1,668,000 | -3.9% | 131,834 | +0.5% | 0.00% | -50.0% |
| Q4 2016 | $1,736,000 | +9.4% | 131,224 | +95.7% | 0.00% | 0.0% |
| Q3 2016 | $1,587,000 | +250.3% | 67,046 | +326.4% | 0.00% | – |
| Q2 2016 | $453,000 | -9.8% | 15,722 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $502,000 | -18.1% | 15,722 | +10.4% | 0.00% | 0.0% |
| Q4 2015 | $613,000 | +31.5% | 14,241 | +5.0% | 0.00% | 0.0% |
| Q3 2015 | $466,000 | -21.8% | 13,557 | +4.4% | 0.00% | 0.0% |
| Q2 2015 | $596,000 | +2.1% | 12,985 | +3.9% | 0.00% | 0.0% |
| Q1 2015 | $584,000 | +79.1% | 12,497 | +22.8% | 0.00% | – |
| Q4 2014 | $326,000 | +29.9% | 10,175 | -2.0% | 0.00% | – |
| Q3 2014 | $251,000 | – | 10,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aravt Global | 3,071,878 | $131,354,000 | 13.28% |
| BANBURY PARTNERS LLC | 480,179 | $20,532,000 | 8.33% |
| Krensavage Asset Management, LLC | 585,170 | $25,022,000 | 7.98% |
| Hound Partners | 6,980,266 | $298,476,000 | 6.77% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 295,000 | $12,614,000 | 4.25% |
| GIOVINE CAPITAL GROUP LLC | 59,805 | $2,557,000 | 3.72% |
| ATERNALIS CAPITAL LLC | 130,000 | $5,559,000 | 3.65% |
| Asymmetry Capital Management, L.P. | 51,430 | $2,199,000 | 3.32% |
| Orbimed Advisors | 6,664,100 | $284,957,000 | 2.58% |
| Pennant Capital Management, LLC | 2,321,581 | $99,271,000 | 2.52% |